Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00124735 | A Study to Determine the Dose Requirements of Rocuronium Bromide (Zemuron®) in Pediatric and Adolescent Subjects (21048)(COMPLETED)(P05797) | PHASE3 | COMPLETED | 149 | — | — | Oct 1, 2004 | Sep 1, 2007 | Aug 24, 2016 | - | — |
Total dose from administration of intubating dose to reappearance of T3 (the third twitch of a Train of Four \[TOF\] stimulation) after the last maintenance bolus dose or discontinuation of Zemuron (rocuronium) infusion (Per protocol \[PP\] data set)
| Arm | Type | Description |
|---|---|---|
| Rocuronium bolus maintenance | EXPERIMENTAL | Rocuronium bolus maintenance |
| Rocuronium continuous infusion maintenance | EXPERIMENTAL | Rocuronium continuous infusion maintenance |
| Name | Type | Description |
|---|---|---|
| Rocuronium bolus maintenance | DRUG | Subjects received a bolus dose of rocuronium for intubation followed by bolus doses for maintenance of muscle relaxation |
| rocuronium continuous infusion maintenance | DRUG | Subjects received a bolus dose of rocuronium for intubation followed by continuous infusion of rocuronium for maintenance of muscle relaxation |
Inclusion Criteria: * Male and female subjects from birth up to 17 years of age who are scheduled for surgery with an anticipated duration of anesthesia of about 2 hours or more requiring a maintenance muscle relaxation dose(s). Exclusion Criteria: * Subjects whose parent(s) or legal guardian(s) ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Masimo Corporation | MASI | 1 | PHASE1 | Diprivan , Astra-Zeneca |
| Cardinal Health, Inc. | CAH | 1 | — | Undisclosed |
| Medtronic Plc | MDT | 1 | NA | Undisclosed |